Provectus Biopharma Ownership Update

TL;DR

Provectus Biopharma (PVCT) filing shows ownership change by Pershing Edward.

AI Summary

On December 6, 2024, an amendment (SC 13D/A) was filed regarding Provectus Biopharmaceuticals, Inc. The filing indicates a change in beneficial ownership by Pershing Edward, located at 2220 Southerland Ave, Knoxville, TN 37919. The filing date of the event requiring this amendment was December 2, 2024.

Why It Matters

This filing signals a potential shift in control or significant stakeholding in Provectus Biopharmaceuticals, Inc., which could influence the company's strategic direction and stock performance.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can indicate significant events, but without more details on the nature of the change, the risk is moderate.

Key Numbers

• 20241206 — Filing Date (Date of the SC 13D/A filing.)
• 20241202 — Event Date (Date of the event requiring the filing.)

Key Players & Entities

• PROVECTUS BIOPHARMACEUTICALS, INC. (company) — Subject Company
• Pershing Edward (person) — Filing Person
• Heather Raines (person) — Person Authorized to Receive Notices

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
• $2,164,658 — k which are issuable upon conversion of $2,164,658 aggregate principal amount and accrued
• $5,797,500 — s: The Issuer has issued an aggregate $5,797,500 principal amount of secured convertible
• $4,140,223 — om April 13, 2018 to November 29, 2024, $4,140,223 principal amount of the Notes plus inte
• $2.862 — Stock”) at a conversion price of $2.862 per share in accordance with the terms
• $50,000 — te in the aggregate principal amount of $50,000 held by the Reporting Person automatica

Filing Documents

• formsc13da.htm (SC 13D/A) — 65KB
• 0001493152-24-049162.txt ( ) — 67KB

From the Filing

SC 13D/A 1 formsc13da.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Provectus Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74373P108 (CUSIP Number) Heather Raines 800 S. Gay Street, Suite 1610 Knoxville, TN 37929 (866) 594-5999 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 2, 2024 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 2 of 5 SCHEDULE 13D CUSIP No. 74373P108 1 NAMES OF REPORTING PERSONS Edward Pershing, CPA 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS (See Instructions) PF, BK 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) 6 CITIZENSHIP OR PLACE OF ORGANIZATION U.S.A. NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 35,700,747 (1) 8 SHARED VOTING POWER 712,350 (2) 9 SOLE DISPOSITIVE POWER 35,700,747 (1) 10 SHARED DISPOSITIVE POWER 712,350 (2) 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 36,413,097 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 8.03% 14 TYPE OF REPORTING PERSON (See Instructions) IN (1) Includes 176,000 shares of common stock owned directly by the Reporting Person, 2,822,030 shares of common stock owned by the Reporting Person through a retirement plan, 8,490,072 shares of common stock issuable upon exercise of stock options that are currently exercisable, 17,200,600 shares of common stock issuable upon conversion of 1,720,060 shares of Series D-1 Convertible Preferred Stock held by the Reporting Person, and 7,563,445 shares of common stock issuable upon conversion of 756,345 shares of Series D-1 Convertible Preferred Stock which are issuable upon conversion of $2,164,658 aggregate principal amount and accrued interest of convertible promissory notes held by the Reporting Person. (2) Includes 60,600 shares of common stock owned by the Reporting Person’s spouse, 16,500 shares of common stock owned by the Reporting Person’s spouse through a retirement plan, 3,750 shares of common stock held as custodian for a grandchild, and 81,500 shares of common stock owned by Mr. P’s Foundation, a nonprofit corporation of which the Reporting Person is an affiliate. Page 3 of 5 This Amendment No. 1 (“Amendment No. 1”) amends and supplements the Statement on Schedule 13D filed by Edward Pershing (the “Reporting Person”) with the Securities and Exchange Commission on July 3, 2024 (the “Original Schedule 13D,” and together with this Amendment No. 1, the “Schedule 13D”) with respect to the shares of common stock, par value $0.001 per share (“Common Stock”), of Provectus Biopharmaceuticals, Inc. (the “Issuer”). Capitalized terms used herein and not otherwise defined in this Amendment No. 1 shall have the meanings set forth in the Original Schedule 13D. This Amendment No. 1 amends Items 3, 4 and 5(a), (b) and (c), as set forth below. Item 3. Source and Amount of Funds or Other Consideration Item 3 of the Schedule 13D is hereby amended and restated in its entirety as follows: The Issuer has issued an aggregate $5,797,500 principal amount of secured convertible promissory notes to the Reporting Person on various dates from April 13, 2018 to October 16, 2024 (the “Notes”). On various dates from April 13, 2018 to November 29, 2024, $4,140,223 principal amount of the Notes plus interest converted into 1,452,012 shares of the Issuer’s Ser

View Full Filing

View this SC 13D/A filing on SEC EDGAR